To evaluate the efficacy of long-term administration of M3 muscarinic acetylcholine receptor (M3R) agonists for Sjögren’s syndrome (SS), we evaluated 62 patients with SS who were treated at our hospital for more than 8 years. Patients receiving M3R agonist therapy (n=46) had significantly improved salivary flow rate at one year after treatment initiation compared with before treatment, and this improvement was maintained for 8 years. Patients without M3R agonist therapy (n=16) had a significantly decreased salivary flow rate at 7 years after treatment initiation compared with before treatment. Multivariate analysis revealed that both the salivary flow rate and sonographic findings of the parotid glands before treatment were significant predictors of the efficacy of M3R agonist therapy in patients with SS (
p<0.05). M3R agonists improve the salivary flow rate, especially in the early stage of SS. Our data suggest that early initiation and long-term continuation of M3R agonist therapy are important in the treatment of xerostomia in patients with SS.
View full abstract